A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Study Summary

This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.

Conditions

Pneumococcal Vaccines

Interventions / Drugs

31-valent pneumococcal conjugate vaccine Seasonal Influenza Vaccine (SIV) (Flublok)Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1390 participants

Primary Completion—

Lead SponsorVaxcyte, Inc.

Data Retrieved2026-04-11 04:24:14.205331+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.